Blog

MEDINA, OHIO / ACCESS Newswire / July 31, 2025 / Pleasant Valley Corporation (PVC)-a leading U.S. facility, construction and real estate services provider headquartered in Medina, Ohio-has formed a strategic partnership with Canadian facility management company, Dexterra Group Inc. (TSX:DXT). Through a minority equity investment in PVC, Dexterra is positioned to expand service capabilities and geographic reach across North America.

For PVC, the partnership with Dexterra represents a complementary match. Dexterra’s strength in self-performing maintenance and extensive background in both public and private sector support services, including complex contracts like public-private partnerships (P3), will be a significant benefit to PVC clients.

PVC’s distributed service model, which incorporates a proprietary facility management technology, PVC Connect™, along with its quality vendor network and service to long-standing client relationships that include Fortune 500 companies, will add significant scale and layers of capabilities to the partnership across North America.

Both companies will benefit from shared industry knowledge, greater resources, and strategic alignment-enhancing services for clients and creating new growth opportunities for employees.

Founded in 1976 by co-CEOs Barbara and Gino Faciana, PVC offers a full range of facility services, including integrated facility management. The company employs over 300, including a leadership team that is led by the Faciana’s four children and their spouses. PVC anticipates no changes to its leadership, shareholders or staff throughout the partnership. Dexterra, a publicly traded company, employs more than 9,000 who deliver support services for the management and operation of infrastructure across Canada and the U.S.

“This partnership with Dexterra will allow us to add a range of resources, expand our technological platform, grow our service offerings for our customers, and scale faster than we could on our own,” said Gino Faciana.

Co-CEO Barbara Faciana added, “The upside is that this creates benefits for everyone involved. It enhances our service offerings without disrupting existing customer relationships or agreements, while also creating new opportunities for our employees to grow and collaborate with the Dexterra team.”

“We are excited to announce our investment in PVC,” said Mark Becker, Chief Executive Officer, Dexterra Group. “PVC’s reputation, culture, and values align very well with Dexterra. Their capabilities and market focus both complement and build our U.S.-based platform supporting long-term profitable growth. The Faciana family will continue to manage the business, and we are looking forward to a long and successful working relationship.”

Information about PVC is available at PleasantValleyCorporation.com. Details about Dexterra are available at Dexterra.com.

About Pleasant Valley Corporation:
Pleasant Valley Corporation was founded in 1976 to provide facility management, construction and real estate services across the U.S.

About Dexterra Group Inc.:
Powered by people, Dexterra brings best-in-class regional expertise to every challenge and delivers innovative solutions, giving clients confidence in their day-to-day operations. Dexterra employs more than 9,000 people, delivering a range of support services for the management and operation of infrastructure across Canada and the U.S. Activities include a comprehensive range of integrated facilities management services, industry-leading workforce accommodation solutions, and other support services for diverse clients in the public and private sectors.

Contact Information

Kurt Kleidon
President, Kleidon & Associates
kurt@kleidon.com
330-666-5984

SOURCE: Pleasant Valley

View the original press release on ACCESS Newswire

VIRGINIA BEACH, VA / ACCESS Newswire / August 4, 2025 / Inspire Veterinary Partners, Inc. (NASDAQ:IVP) (“Inspire” or the “Company”), an owner and provider of pet health care services throughout the U.S., today announced that it has entered into a securities purchase agreement for the issuance and sale of securities under a new convertible preferred stock transaction. The consideration, consisting of a combination of cash and transferred securities, was valued at $1.00 per share.

The gross proceeds to the Company from the offering are expected to be up to $10 million, including $6 million expected to be received through the investment of cash and securities at the first closing, and up to $4 million of cash that may be funded at one or more additional closings, at the election of the investors. The Company intends to use the net proceeds from the offering for general working capital and acquisitions of additional veterinary practices. The proceeds will also help to address current Nasdaq deficiencies around Shareholders Equity and extend cash on hand to maintain operations and extend runway.

“As communicated earlier in 2025, the team at IVP is executing on our growth strategy and this offering helps to facilitate our objectives,” said President, Chairman and CEO, Kimball Carr, “With new acquisitions onboarded and record clinical hiring this year, I could not be prouder of our team for the continued progress being made across all departments within IVP.”

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.

About Inspire Veterinary Partners, Inc.

Inspire Veterinary Partners is an owner and provider of pet health care services throughout the US. As the Company expands, it expects to acquire additional veterinary hospitals, including general practice, mixed animal facilities, and critical and emergency care. For more information, please visit: www.inspirevet.com.

Facebook | LinkedIn | X

Forward-Looking Statements

This press release contains forward-looking statements regarding the Company’s current expectations. These statements are not guarantees of future performance and are subject to certain risks, uncertainties and assumptions that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, statements by the Company relating to the completion of the offering, the satisfaction of customary closing conditions related to the offering, the intended use of proceeds from the offering, receipt of Stockholder Approval as well as risks and uncertainties related to the satisfaction of customary closing conditions related to anticipated acquisitions, or factors that result in changes to the Company’s anticipated results of operations related to acquisitions. These and other risks and uncertainties are described more fully in the section captioned “Risk Factors” in the Company’s public filings made with the Securities and Exchange Commission, including its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. Forward-looking statements contained in this announcement are made as of this date, and the Company undertakes no duty to update such information except as required under applicable law.

Investor Contact

CoreIR
Matt Blazei
516-386-0430
mattb@coreir.com

Press Contact

CORE IR
Matthew Cossel
pr@coreir.com

General Inquires

Morgan Wood
Mwood@inspirevet.com

SOURCE: INSPIRE VETERINARY PARTNERS, INC.

View the original press release on ACCESS Newswire

Led by a team of African researchers, first doses of the novel T cell-inducing GRAdHIVNE1 vaccine candidate have been given.

HARARE, ZIMBABWE, ROME, ITALY, NEW YORK, NY, AND CAMBRIDGE, MA / ACCESS Newswire / August 4, 2025 / The Mutala Trust, ReiThera Srl (ReiThera), the Ragon Institute of Mass General Brigham, MIT, and Harvard (the Ragon Institute), and IAVI are pleased to announce that the first doses of an investigational HIV vaccine candidate have been administered. The vaccine candidate, Gorilla Adenovirus Vectored HIV Networked Epitopes Vaccine (GRAdHIVNE1), was first administered on July 28, 2025, at the Mutala Trust clinical trial site in Harare, Zimbabwe. This effort is made possible by a global collaboration and a team of African principal investigators who will lead the clinical research in South Africa and Zimbabwe (listed below). Vaccine immunogenicity will also be assessed locally by a network of state-of-the-art African research institutes: Cape Town HVTN Immunology Laboratory in Cape Town, African Health Research Institute in Durban, and the National Institute for Communicable Diseases in Johannesburg, South Africa.

This Phase 1, first-in-human clinical trial will enroll approximately 120 healthy adults aged 18-50 years, including 48 people living with HIV who are virally suppressed on antiretroviral therapy (ART). The trial is designed to assess the safety and immunogenicity of the vaccine candidate in people living with and without HIV. Participants will receive either one or two doses of the investigational vaccine or a placebo and will be monitored over a period of 19 months for safety and immune responses.

This clinical trial, IAVI C114, is sponsored by IAVI. GRAdHIVNE1 has been made possible by a collaborative effort. ReiThera developed the GRAd viral vector platform and manufactured the vaccine candidate, while the Ragon Institute designed the immunogen using novel strategies to identify protective HIV epitopes and facilitate their targeting by T cells. This clinical program is funded by the Gates Foundation.

The IAVI C114 clinical trial is taking place at three clinical trial sites: the Mutala Trust Clinical Trial Site, in Harare, Zimbabwe; the Desmond Tutu Health Foundation (DTHF), in Cape Town, South Africa; and the Africa Health Research Institute (AHRI), in Durban, South Africa. To determine the vaccine candidate’s potential for relevance in sub-Saharan Africa, where disease burden is greatest, it is essential that the candidate be tested within communities affected by the epidemic.

“This is a landmark moment for South Africa, Zimbabwe, and the continent. It shows the power of true partnership: IAVI’s sponsorship, ReiThera’s GRAd technology, the Ragon Institute’s innovative immunogen built on decades of science, and African investigators co-leading every phase of the trial. We are edging closer to an HIV vaccine, made possible by global collaboration, with clinical trials conducted in Africa, for Africa, and for the world.” said Dr. Tariro Makadzange, Clinical Trial Lead, Mutala Trust.

“This trial represents the future of vaccine development, rooted in Africa, built through global partnerships, and designed for the communities most affected by HIV,” said Dr. Vincent Muturi-Kioi, HIV Vaccines Product Development Team Lead at IAVI.

The vaccine candidate is designed to engage the immune system to recognize and target critical structural regions of HIV using a clinically validated, potent, T cell-inducing GRAd vector. This approach will be evaluated to assess the ability of the vaccine candidate to direct strong CD8+ T cell immune responses towards these vulnerable viral regions.

“We are thrilled to be moving insights from our long-term studies of spontaneous elite controllers of HIV toward the development of GRAdHIVNE1 and its testing in Africa. We are truly grateful to the network of global and African partners that have come together to make the IAVI C114 trial a reality,” said Dr. Gaurav Gaiha, Associate Professor of Medicine at Harvard Medical School and Principal Investigator at the Ragon Institute of Mass General Brigham, MIT, and Harvard.

Because CD8+ T cells induced by this vaccine hold promise for targeting HIV-infected cells, this clinical trial will also assess the safety and immune response in people living with HIV. These data will be used to assess the suitability of the vaccine candidate for the development of investigational HIV therapeutic and curative interventions.

“We are enormously pleased with the launch of this Phase 1 trial representing the result of a successful global partnership,” said Stefano Colloca, CEO and co-Founder of ReiThera. “This candidate HIV vaccine, built on our GRAd platform, holds great promise to trigger a strong CD8 response targeting vulnerable viral regions.”

Principal Investigators Leading Clinical Trial Sites:

• Tariro Makadzange, Mutala Trust

• Theodorah Rirhandzu Ndzhukule, DTHF

• Limakatso Lebina, AHRI

About IAVI

IAVI is a global nonprofit scientific organization that works to develop vaccines and antibodies to prevent HIV and other infectious diseases, with a focus on innovation and equitable access. IAVI is the sponsor of this trial. Read more at www.iavi.org.

IAVI media contact

Heather Teixeira
hteixeira@iavi.org

About Mutala Trust

Mutala Trust is founding member of Africa Clinical Research Network (ACRN) and is a site based in Harare, Zimbabwe. It is known for conducting high-quality, ethically sound clinical trials addressing diseases that affect African communities. Mutala is the clinical lead site for the study.

Mutala Trustmedia contact

coms@acrnhealth.com

About ReiThera Srl.

ReiThera Srl, an Italian CDMO specializing in technology and process development as well as GMP manufacturing of viral vectors for genetic vaccines and advanced therapies, is the developer and owner of the GRAd platform used for this HIV vaccine.

ReiThera media contact

communication@reithera.com

About the Ragon Institute of Mass General Brigham, MIT, and Harvard

The Ragon Institute of Mass General Brigham, MIT, and Harvard was established with a collaborative scientific mission among these institutions that brings scientists, clinicians and engineers together to harness the immune system to combat and cure human disease. They contributed to vaccine design. For more information, visit www.ragoninstitute.org

Ragon Institutemedia contact

ragoncommunications@mgh.harvard.edu

SOURCE: IAVI

View the original press release on ACCESS Newswire

New IRS enforcement initiative targets restaurants, salons, and other cash-heavy operations as audit risk rises in 2025

IRVINE, CA / ACCESS Newswire / August 4, 2025 / The IRS is ramping up its scrutiny of “cash-only” businesses in 2025, renewing enforcement efforts aimed at industries known for limited electronic records and underreported income. Restaurants, barbershops, nail salons, convenience stores, and similar businesses could face increased audit activity, according to tax professionals closely following the agency’s shift.

Clear Start Tax, a national tax resolution firm, is advising small business owners who rely on cash transactions to take proactive steps to ensure their books are in order and avoid unnecessary penalties.

“The IRS is targeting businesses with high cash volume because they often lack digital documentation, which makes them easier to flag for underreporting,” said a spokesperson for Clear Start Tax. “This year, the agency has new tools and data analytics that make it much easier to spot discrepancies in cash-heavy operations.”

The enforcement push comes as part of a broader IRS strategy to close the “tax gap” – the difference between taxes owed and taxes actually collected – with the help of increased funding and advanced AI audit filters. Officials have stated they will focus on industries with historical patterns of noncompliance, particularly where income may be hidden or underreported.

“We’re seeing a clear pattern: if your business isn’t using point-of-sale systems or bank deposits to track revenue, you’re at greater risk,” the Clear Start Tax spokesperson added. “Even businesses that aren’t intentionally evading taxes could get caught up in this if their recordkeeping is sloppy or inconsistent.”

Clear Start Tax recommends that cash-based businesses conduct internal reviews, reconcile deposits with reported income, and consider working with professionals to prepare for potential audits. The firm has already seen a rise in inquiries from business owners seeking advice on how to respond to IRS notices or suspected underreporting claims.

“Our message is simple – don’t wait for a letter from the IRS. Get ahead of it,” said the spokesperson. “A few small adjustments in how you document income today could save you thousands down the line.”

By answering a few simple questions, taxpayers can find out if they’re eligible for the IRS Fresh Start Program and take the first step toward resolving their tax debt.

The IRS has not announced specific audit targets, but experts say businesses operating with limited digital financial trails are already on the radar.

About Clear Start Tax

Clear Start Tax is a trusted tax resolution firm helping individuals and businesses nationwide resolve IRS debt, navigate audits, and find relief through established IRS programs. With a focus on transparency, compliance, and results, the firm has assisted thousands of taxpayers in regaining control of their financial futures.

Need Help With Back Taxes?

Click the link below:
https://clearstarttax.com/qualifytoday/
(888) 710-3533

Contact Information

Clear Start Tax
Corporate Communications Department
tech@clearstarttax.com
(949) 800-4011

SOURCE: Clear Start Tax

View the original press release on ACCESS Newswire

-Company closes approximately $5.47 million in equity financing in 2Q/3Q25
-TH104 potentially fills a critical National Security Need against Weaponized Fentanyl
–TH023 may fulfill the promise of delivering a safe and effective oral antibody medication against inflammation
-Company Strengthens Operational Leadership, Corporate Governance and Accounting

RED BANK, NJ / ACCESS Newswire / August 4, 2025 / Tharimmune, Inc. (Nasdaq:THAR) (“Tharimmune” or the “Company”), a clinical-stage biotechnology company dedicated to developing innovative therapeutic candidates for inflammation, immunology, and critical unmet medical needs, today issued a comprehensive corporate update highlighting significant advancements across its pipeline. The update underscores the rapid progression of TH104 as a lead asset addressing critical national security risks posed by weaponized fentanyl, and the transformative potential of TH023 in pioneering oral antibody delivery for widespread inflammatory conditions.

The Company has strengthened its financial position by successfully completing several equity financings and securing approximately $5.47 million in gross proceeds before deducting placement and legal fees, during the latter part of the second quarter and continuing into the third quarter of this year. The capital infusion underscores the strong confidence from existing investors, whose continued commitment reflects a clear recognition of the Company’s strategic vision and pipeline potential. We believe these proceeds will strategically accelerate the advancement of TH104, recognizing its paramount importance as a swiftly progressing national security asset, in addition to supporting general corporate purposes vital for the Company’s continued growth and operational efficiency.

“Over the past year, Tharimmune has achieved considerable milestones, particularly in advancing our lead candidate TH104 to a potential NDA with clear direction from FDA on a pathway while demonstrating preclinical success with our oral antibody program, TH023,” stated Sireesh Appajosyula, Chief Executive Officer of Tharimmune. “Our strategic focus on high-impact solutions, from protecting military and first responders to redefining treatment paradigms for chronic inflammatory diseases, reflects our unwavering commitment to patient well-being and shareholder value.”

TH104: A National Security Solution Against Weaponized Fentanyl and High-Potency Opioids

Tharimmune’s lead asset, TH104, a buccal film formulation of nalmefene, has rapidly advanced with a regulatory pathway to address the escalating national security threat posed by weaponized fentanyl and other high-potency opioids like fentanyl.

Addressing an Important National Security Threat: The U.S. government has increasingly recognized fentanyl and its related compounds as significant national security threats due to their extreme potency and potential for mass casualty incidents if weaponized. Incidents such as the 2002 Moscow theater hostage crisis, where aerosolized synthetic opioids were reportedly used, tragically demonstrated the devastating potential of such agents. In this critical context, Tharimmune explicitly positions TH104 as a direct response to this growing threat, aligning with the urgent need for specialized prophylactic medical countermeasures highlighted in recent U.S. Strategic National Stockpile (SNS) market assessments.

Superiority and Convenience over Current Solutions: While existing solutions like naloxone auto-injectors are vital for emergency reversal, they often have a relatively short half-life (e.g., naloxone has a half-life of approximately 60-90 minutes to 2 hours). This can necessitate repeated dosing, particularly with longer-acting or highly potent synthetic opioids like fentanyl, which can have a significantly longer half-life (around 8 hours). TH104, which utilizes nalmefene, offers a crucial advantage with a significantly longer plasma half-life of approximately 8 to 11 hours. This extended duration of action means TH104 provides sustained protection, potentially reducing the need for continuous monitoring and potential multiple redosing in a high-risk environment. Furthermore, TH104’s buccal film formulation allows for rapid and convenient administration, a critical benefit for military personnel and chemical incident responders who may be wearing full protective gear, where intramuscular injections can be impractical or delayed.

Positive FDA Feedback and Expedited Pathway: In a pivotal development, Tharimmune previously announced positive feedback from the FDA regarding the New Drug Application (NDA) path for TH104. Crucially, the FDA confirmed that no additional clinical trials appear to be necessary prior to a 505(b)(2) NDA submission for TH104’s proposed indication: “Temporary Prophylaxis of Respiratory and/or Nervous System Depression in Military Personnel and Chemical Incident Responders Entering an Area Contaminated with High-Potency Opioids.” This expedited pathway allows Tharimmune to leverage existing extensive safety and efficacy data for nalmefene, combined with the Company’s human pharmacokinetic data, enabling an “in silico” (computer simulation) submission model, significantly accelerating its potential availability.

Robust Clinical Data and Metabolic Profile: Positive Phase 1 clinical data for TH104, presented at prominent conferences including Digestive Disease Week (DDW) and the European Association for the Study of the Liver (EASL) International Liver Congress in May 2025, highlights its distinct pharmacokinetic and metabolic profile. The data demonstrated that buccal administration achieves systemic exposure to nalmefene with reliable and predictable absorption and delayed phase 1 metabolism, potentially offering advantages for individuals with impaired liver function as potential added benefit. This scientific validation underpins TH104’s suitability as a critical medical countermeasure.

Strengthened Expertise in National Security: Tharimmune has strategically fortified its leadership to advance TH104’s national security mission. James Gordon Liddy (CDR US Navy SEAL (Ret)), a renowned counter-terrorism and critical infrastructure expert, has been appointed to the Board of Directors and serves as a Key Strategic Advisor. His unparalleled expertise in national security and preparedness, including his role in designing and coordinating policy for the Global War on Terrorism and architecting the Navy’s Anti-Terrorism Force Protection Plan, provides invaluable guidance for the development and potential deployment of TH104 within national security frameworks.

The Promise of Oral Antibody Delivery

The administration of monoclonal antibodies (mAb), while highly effective for a range of chronic diseases, has historically been limited to intravenous (IV) infusions or subcutaneous injections. These parenteral routes often necessitate frequent clinic visits, specialized medical personnel for administration, and can be painful or inconvenient for patients, impacting adherence to long-term therapy. The development of an effective oral delivery method for antibodies would truly be a “game-changer,” revolutionizing patient access, convenience, and quality of life by transforming a complex, clinic-bound procedure into a simple, at-home pill. Overcoming the formidable physiological barriers of the gastrointestinal tract – including harsh pH environments, enzymatic degradation, and limited permeability for large molecules – has been a persistent challenge in biopharmaceutical development. We believe Tharimmune’s TH023 program is at the forefront of addressing this critical unmet need.

TH023: Pioneering Oral Antibody Delivery for Inflammatory Conditions

Tharimmune is developing TH023, a novel oral monoclonal antibody targeting Tumor Necrosis Factor-alpha (TNF-alpha), licensed through Intract Pharma (UK), which could potentially revolutionize the delivery of biologic therapies for a wide array of inflammatory conditions.

Preclinical Validation: In an advancement for oral antibody delivery, Tharimmune in the past year announced positive preclinical results for TH023. Leveraging a proprietary protease enzyme stabilized platform (Soteria^®), preclinical studies in a murine model successfully demonstrated oral delivery of infliximab, achieving serum concentrations significantly higher than standard therapeutic levels. The studies confirmed enzymatic protection and successful in vivo delivery to both local colonic tissue and systemic circulation, highlighting its potential for treating both local gastrointestinal diseases (like Inflammatory Bowel Disease) and systemic inflammatory conditions. This proprietary formulation showed superior tissue penetration compared to traditional permeation enhancers, underscoring the innovative nature of TH023.

Revolutionizing Patient Care and Market Potential: This program originated from a strategic global licensing agreement with Intract Pharma for INT-023 (now TH023) in September 2024. Traditionally, TNF-alpha inhibitors like infliximab (Remicade^®) are administered via intravenous infusions or subcutaneous injections, which may be burdensome for patients. TH023 aims to overcome these challenges, offering a convenient oral pill form that could dramatically improve patient compliance, quality of life, and reduce healthcare system burdens. With the global infliximab market in the multibillions, an oral formulation represents a substantial commercial opportunity by providing a differentiated, patient-preferred option that broadens access and potentially lowers overall treatment costs.

Future Development: Building on these promising preclinical results, Tharimmune plans to optimize TH023’s formulation and dosing regimen and prepare for a first-in-human clinical trial within the next 12 months, marking a significant step towards bringing this transformative therapy to patients.

Strengthening Corporate Governance and Leadership for Accelerated Growth

Tharimmune has strategically enhanced its leadership and governance structure to support its ambitious pipeline advancements and future growth.

Key Executive and Board Appointments: In addition to the strategic advisory role and Board appointment of James Gordon Liddy, Tharimmune has appointed Sireesh Appajosyula as Chief Executive Officer, leveraging his extensive experience in corporate development and operations. Vincent LoPriore, with decades of financial and investment banking experience, has been appointed Executive Chairman of the Board, further solidifying strategic oversight. The Board has also been strengthened by the appointments of Clay Kahler, bringing entrepreneurial leadership and expertise in life sciences manufacturing and clinical innovation, and Gary Stetz, a seasoned financial executive with extensive experience in accounting, finance, and corporate governance. These appointments collectively enhance the company’s operational, financial, and strategic capabilities as it advances its critical programs.

Tharimmune remains dedicated to leveraging its innovative platforms to address high unmet medical needs and drive significant value for patients and shareholders alike.

About Tharimmune, Inc.

Tharimmune is a clinical-stage biotechnology company developing a diverse portfolio of therapeutic candidates in immunology, inflammation and oncology. Its lead clinical asset, TH104, is being developed for a specific indication via a 505(b)2 pathway for respiratory and/or nervous system depression in military personnel and chemical incident responders who may encounter environments contaminated with high-potency opioids. The expanded pipeline includes other indications for TH104, such as chronic pruritus in primary biliary cholangitis and TH023, a new approach to treating autoimmune diseases along with an early-stage multispecific biologic platform targeting unique epitopes against multiple solid tumors through its proprietary EpiClick^™ Technology. The Company has a license agreement with OmniAb, Inc. to access their antibody discovery technology for targeting specified disease markers. Tharimmune continues to position itself as a leader in patient-centered innovation while working to deliver long-term value for shareholders. For more information, visit: www.tharimmune.com.

Forward Looking Statements

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, contained in this press release, including statements regarding the timing and design of Tharimmune’s future Phase 2 trial, Tharimmune’s strategy, future operations, future financial position, projected costs, prospects, plans and objectives of management, are forward-looking statements. The words “anticipate,” “believe,” “continue,” “could,” “depends,” “estimate,” “expect,” “intend,” “may,” “ongoing,” “plan,” “potential,” “predict,” “project,” “target,” “should,” “will,” “would,” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. The Company may not actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements. Factors that may cause such differences, include, but are not limited to, those discussed under Risk Factors set forth in our Annual Report on Form 10-K for the year ended December 31, 2024 and other periodic reports filed by the Company from time to time with the Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent the Company’s views as of the date of this release. Subsequent events and developments may cause the Company’s views to change; however, the Company does not undertake and specifically disclaims any obligation to update or revise any forward-looking statements to reflect new information, future events or circumstances or to reflect the occurrences of unanticipated events, except as may be required by applicable law. These forward-looking statements should not be relied upon as representing the Company’s views as of any date subsequent to the date of this release.

Contacts:

Tharimmune, Inc.
ir@tharimmune.com

SOURCE: Tharimmune Inc.

View the original press release on ACCESS Newswire

The funding accelerates the company’s mission to eliminate manual data operations by combining real-time monitoring, traceability and agentic AI to boost enterprise data reliability at scale.

CINCINNATI, OH / ACCESS Newswire / August 4, 2025 / Pantomath, an AI-powered automated data operations platform, today announced it has secured $30 million in Series B funding to expand beyond traditional data observability to become the Operating System for Data Operations. The round was led by General Catalyst, a global investment and transformation company. Existing investors Sierra Ventures, Bowery Capital and Epic Ventures also participated in the round along with Hitachi Ventures, Cintrifuse Capital and Foster Ventures. This new round follows Pantomath’s $14 million Series A in late 2023 led by Sierra Ventures and will accelerate product innovation, go-to-market expansion, and strategic hiring to meet surging enterprise demand to automate manual tasks with AI DRE (Data Reliability Engineer) agents.

“Enterprises today grapple with highly manual and reactive data operations to support their data pipelines and analytics products. 74% of organizations rely on downstream end-users to discover data reliability problems, leading to isolated manual troubleshooting and incident management that according to a CDO survey takes 90% of organizations hours to weeks to resolve. Data downtime, unreliable data, and failure to meet SLAs are common occurrences in large enterprises,” said Somesh Saxena, co-founder and President of Pantomath who lived through these challenges as a data leader at General Electric prior to co-founding Pantomath in 2022.

“Our current foundation of auto-discovered data health graphs that automates cross-platform data monitoring positions us well to expand beyond real-time detection of data issues into full self-resolution of incidents with autonomous AI DRE agents,” said Shashank Saxena, co-founder and CEO of Pantomath.

Since its initial product launch in 2023, Pantomath has experienced rapid growth across industries and now supports mission-critical analytics pipelines at leading Fortune 500 companies. “Pantomath slashed the time our teams spent tracking down broken pipelines. With their automated root-cause analysis, we resolve issues in minutes (not hours, days or weeks) so our business partners always have trusted data. Our data operations teams start and end their day with Pantomath,” said Andrew Connolly, Director of Site Reliability Engineering, WEX.

The company also announced that Quentin Clark, a Managing Director at General Catalyst, is joining its board of directors. At General Catalyst, Clark has helped scale companies such as Glean, Windsurf (acquired by Cognition), and Neon (acquired by Databricks). “Enterprise data operations have remained stubbornly complex despite years of tooling. Pantomath is changing that with AI-native enterprise software that doesn’t just surface problems, it solves them. This is a shift from software as a passive tool to software that enacts work across the enterprise,” said Clark. “It’s the systems-of-record to systems-of-work transformation we’ve long envisioned.”

About Pantomath

Pantomath delivers automated data operations for modern enterprises, unifying real-time monitoring, cross-platform lineage, AI-driven root-cause and impact analysis into a single platform. By eliminating manual troubleshooting and reducing data downtime, Pantomath restores trust in data and unlocks productivity across analytics teams. The company is headquartered in Cincinnati, Ohio. Learn more at pantomath.com.

About General Catalyst

General Catalyst is a global investment and transformation company that partners with the world’s most ambitious entrepreneurs to drive resilience and applied AI.

We support founders with a long-term view who challenge the status quo, partnering with them from seed to growth stage and beyond.

With offices in San Francisco, New York City, Boston, Berlin, Bangalore, and London, we have supported the growth of 800+ businesses, including Airbnb, Anduril, Applied Intuition, Commure, Glean, Guild, Gusto, Helsing, Hubspot, Kayak, Livongo, Mistral, Ramp, Samsara, Snap, Stripe, Sword, and Zepto.

For more: www.generalcatalyst.com, @generalcatalyst

Media Contact:

Nina Pfister
MAG PR on behalf of Pantomath
E: nina@mooringadvisorygroup.com

SOURCE: Pantomath

View the original press release on ACCESS Newswire